Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Herrmann

Showing results (221-230 of 721) with videos related to

Pageof 73
Sort By:
Seminars in Nuclear Medicine|April 15, 2020
Cardiac PET/MRI: Current Clinical Status and Future PerspectivesChristoph Rischpler, Johannes Siebermair, Lukas Kessler, et al.
Nuclear Medicine Communications|January 25, 2020
Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumorsManuel Weber, Lukas Kessler, Benedikt Schaarschmidt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 18, 2017
Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing TumorsSusanne Lütje, Danny Gerrits, Janneke D Molkenboer-Kuenen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 5, 2010
PET/CT with 18F-FLT is unlikely to cause significant hepatorenal or hematologic toxicityMalik E Juweid, Damita Thomas, Yusuf Menda, et al.
BMC Cancer|April 18, 2020
Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from <sup>68</sup>Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficientManuel Weber, Lukas Kessler, Benedikt Schaarschmidt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 14, 2017
The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-AnalysisMartin Barrio, Johannes Czernin, Stefano Fanti, et al.
Seminars in Nuclear Medicine|May 27, 2022
A Role for PET/CT in Response Assessment of Malignant Pleural MesotheliomaPatrick Sandach, Robert Seifert, Wolfgang P Fendler, et al.
Cancers|May 16, 2023
Update on Calcitonin Screening for Medullary Thyroid Carcinoma and the Results of a Retrospective Analysis of 12,984 Patients with Thyroid NodulesMartina Broecker-Preuss, Dietmar Simon, Mirka Fries, et al.
Medical Physics|November 26, 2024
Detection and quantification of small and low-uptake lesions for differentiated thyroid carcinoma using non-time-of-flight iodine-124 PET/MRIMaike E Lindemann, Walter Jentzen, David Kersting, et al.
Oncotarget|March 13, 2015
11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myelomaKatharina Lückerath, Constantin Lapa, Christa Albert, et al.
Pageof 73

Showing results (221-230 of 721) with videos related to

Sort By:
Pageof 73
Seminars in Nuclear Medicine|April 15, 2020
Cardiac PET/MRI: Current Clinical Status and Future PerspectivesChristoph Rischpler, Johannes Siebermair, Lukas Kessler, et al.
Nuclear Medicine Communications|January 25, 2020
Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumorsManuel Weber, Lukas Kessler, Benedikt Schaarschmidt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 18, 2017
Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing TumorsSusanne Lütje, Danny Gerrits, Janneke D Molkenboer-Kuenen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 5, 2010
PET/CT with 18F-FLT is unlikely to cause significant hepatorenal or hematologic toxicityMalik E Juweid, Damita Thomas, Yusuf Menda, et al.
BMC Cancer|April 18, 2020
Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from <sup>68</sup>Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficientManuel Weber, Lukas Kessler, Benedikt Schaarschmidt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 14, 2017
The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-AnalysisMartin Barrio, Johannes Czernin, Stefano Fanti, et al.
Seminars in Nuclear Medicine|May 27, 2022
A Role for PET/CT in Response Assessment of Malignant Pleural MesotheliomaPatrick Sandach, Robert Seifert, Wolfgang P Fendler, et al.
Cancers|May 16, 2023
Update on Calcitonin Screening for Medullary Thyroid Carcinoma and the Results of a Retrospective Analysis of 12,984 Patients with Thyroid NodulesMartina Broecker-Preuss, Dietmar Simon, Mirka Fries, et al.
Medical Physics|November 26, 2024
Detection and quantification of small and low-uptake lesions for differentiated thyroid carcinoma using non-time-of-flight iodine-124 PET/MRIMaike E Lindemann, Walter Jentzen, David Kersting, et al.
Oncotarget|March 13, 2015
11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myelomaKatharina Lückerath, Constantin Lapa, Christa Albert, et al.
Pageof 73